| Code | CSB-RA624104MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to HB-0017, targeting human interleukin-17A (IL17A), a proinflammatory cytokine central to immune-mediated pathology. IL17A is primarily produced by Th17 cells and plays a critical role in host defense against extracellular pathogens by recruiting neutrophils and inducing inflammatory mediators. Dysregulated IL17A signaling contributes to the pathogenesis of numerous autoimmune and inflammatory conditions, including psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease. Elevated IL17A levels have also been implicated in asthma, multiple sclerosis, and certain cancer microenvironments where it promotes tumor progression and angiogenesis.
HB-0017 serves as a reference therapeutic antibody that neutralizes IL17A activity by preventing its interaction with the IL17 receptor. This biosimilar antibody provides researchers with a valuable tool for investigating IL17A-mediated inflammatory pathways, exploring disease mechanisms in autoimmune disorders, evaluating therapeutic intervention strategies, and conducting preclinical studies in immunology and inflammation research.
There are currently no reviews for this product.